<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827553</url>
  </required_header>
  <id_info>
    <org_study_id>2009-014476-21</org_study_id>
    <nct_id>NCT01827553</nct_id>
  </id_info>
  <brief_title>Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy</brief_title>
  <acronym>CONKO-007</acronym>
  <official_title>Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized trial examines the effectiveness of chemoradiotherapy compared to
      chemotherapy alone after induction chemotherapy with 3 cycles of gemcitabine or 6 cycles of
      FOLFIRINOX in patients with locally advanced, non resectable and non-metastatic pancreatic
      cancer. Chemotherapeutic agent in chemoradiotherapy is gemcitabine administered in 5 cycles,
      the agent and its administration for sole chemotherapy is determined by induction
      chemotherapy. Operability of tumor is evaluated at week 11 after randomisation. Patients will
      be followed for the duration of therapy and for 5 years after the last study treatment.
      Overall survival at the end of follow up is defined as primary endpoint. Secondary endpoints
      are tumor-free survival, rate of local recurrence or local progression, rate of distant
      metastasis, acute and late toxicity of the chemoradiotherapy, quality of life, rate of
      remission, rate of curative resections (R0) after chemotherapy and chemoradiotherapy. It is
      planned to include a total number of 830 patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor-free survival</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of local recurrence or local progression</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of distant metastasis</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicity of the chemoradiotherapy</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of remission</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of curative resections (R0) after chemotherapy and chemoradiotherapy</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">830</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Induction CT, chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy with gemcitabine or FOLFIRINOX; Radiotherapy, 28 x 1.8 Gy; Chemotherapy, gemcitabine;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction CT, chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction chemotherapy with gemcitabine or FOLFIRINOX; Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction chemotherapy with gemcitabine or FOLFIRINOX</intervention_name>
    <description>According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m^2 2 h infusion, folinic acid 400 mg/ m^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m^2 for 90 minutes, bolus application 5-FU 400 mg/m^2 followed by 46h infusion of 5-FU 2400 mg/m^2)</description>
    <arm_group_label>Induction CT, chemoradiotherapy</arm_group_label>
    <arm_group_label>Induction CT, chemotherapy</arm_group_label>
    <other_name>all brands of gemcitabine and FOLFIRINOX components are allowed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy, 28 x 1.8 Gy</intervention_name>
    <description>Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.</description>
    <arm_group_label>Induction CT, chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy, gemcitabine</intervention_name>
    <description>5 cycles of 300 mg/m^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m^2/d</description>
    <arm_group_label>Induction CT, chemoradiotherapy</arm_group_label>
    <other_name>all brands of gemcitabine are allowed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy</intervention_name>
    <description>Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m^2/d gemcitabine infusions FOLFIRINOX: 6 cycles</description>
    <arm_group_label>Induction CT, chemotherapy</arm_group_label>
    <other_name>all brands of gemcitabine and FOLFIRINOX components are allowed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  histologically confirmed adenocarcinoma of the pancreas

          -  no evidence of distant metastasis based on computed tomography of the thorax and
             abdomen

          -  non resectable pancreatic cancer

          -  no evidence of peritoneal carcinosis

          -  ECOG-performance status ≤ 2

          -  signed study-specific consent form prior to therapy

        Exclusion Criteria:

          -  fertile patients who refuse effective contraception during study treatment

          -  synchron second malignant neoplasm except basal cell carcinoma of the skin and
             carcinoma in situ of the cervix after curative therapy

          -  the Inclusion of patients with prior or concurrent malignancy (≤ 5 years prior to
             enrolment in study) must be discussed

          -  chronic inflammatory disease of the intestine

          -  known allergic reactions on study medication

          -  on-treatment participation on other trials

          -  insufficient liver function: Bilirubin &gt; 2,0 mg/dl; SGOT, SGPT, alkaline phosphatase,
             gGT more than 3 times upper limit of normal (after Stent implantation in case of
             obstructive jaundice); cirrhosis of the liver Child B and C

          -  insufficient bone marrow function: WBC &lt; 3,0 x 10^9/l, Platelets &gt; 100 x 10^9/l

          -  serum creatinine &gt; 1,5 mg/dl, creatinin clearance &lt; 60ml/min (or comparable test)

          -  preexisting uncontrolled cardiac disease, signs of cardiac failure, or rhythm
             disturbances requiring therapy, myocardial infarction within the past 6 months,
             unstable angina pectoris, congestive heart failure, New York Heart Association (NYHA)
             class III or IV heart disease

          -  neurological and/or psychiatric diseases: stroke, dementia, epilepsy, psychosis

          -  active intractable or uncontrollable infection, HIV-infection

          -  prior radiotherapy or chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer Fietkau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Strahlenklinik, Universitätsklinikum Erlangen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rainer Fietkau, MD</last_name>
    <phone>++49(0)9131 85</phone>
    <phone_ext>33968</phone_ext>
    <email>st-studiensekretariat@uk-erlangen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabine Semrau, MD</last_name>
    <phone>++49(0)9131 85</phone>
    <phone_ext>33968</phone_ext>
    <email>st-studiensekretariat@uk-erlangen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aachen Universitätsklinikum</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulf Peter Neumann, MD</last_name>
      <email>chirurgie@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Florian Ulmer, MD</last_name>
      <email>fulmer@ukaachen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ulf Peter Neumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florian Ulmer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bayreuth, Klinikum</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludwig Keilholz, MD</last_name>
      <email>ludwig.keilholz@klinikum-bayreuth.de</email>
    </contact>
    <contact_backup>
      <last_name>Alexander Kiani, MD</last_name>
      <email>alexander.kiani@klinikum-bayreuth.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ludwig Keilholz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Kiani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Berlin-Lichtenberg, Sana-Klinikum, Hämatologie/Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>10365</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Berlin, Charité Universitätsmedizin, Hämatologie/Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Sinn, MD</last_name>
      <email>marianne.sinn@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Uwe Pelzer, MD</last_name>
      <email>uwe.pelzer@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Marianne Sinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Uwe Pelzer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bochum, Augusta-Kranken-Anstalt, Hämatologie/Onkologie</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Behringer, MD</last_name>
      <email>behringer@augusta-bochum.de</email>
    </contact>
    <contact_backup>
      <last_name>Michael Brandt</last_name>
      <email>brandt@augusta-bochum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Dirk Behringer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Brandt</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bochum, St. Josef-Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waldemar Uhl, MD</last_name>
      <email>w.uhl@klinikum-bochum.de</email>
    </contact>
    <contact_backup>
      <last_name>Peter R Ritter, MD</last_name>
      <email>anke.reinacher@rub.de</email>
    </contact_backup>
    <investigator>
      <last_name>Waldemar Uhl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anke Reinacher-Schick, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bochum Knappschaftskrankenhaus</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolff Schmiegel, MD</last_name>
      <email>meduni-kkh@ruhr-uni-bochum.de</email>
    </contact>
    <contact_backup>
      <last_name>Michael Pohl, MD</last_name>
      <email>michael.pohl-4@rub.de</email>
    </contact_backup>
    <investigator>
      <last_name>Wolff Schmiegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Pohl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brandenburg Städtisches Klinikum</name>
      <address>
        <city>Brandenburg</city>
        <zip>14770</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René Mantke, MD</last_name>
      <email>mantke@klinikum-brandenburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Peter Markus Deckert, Deckert</last_name>
      <email>deckert@klinikum-brandenburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>René Mantke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Markus Deckert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bremen Klinikum Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann Ockenga, MD</last_name>
      <email>johann.ockenga@klinikum-bremen-mitte.de</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Martin, MD</last_name>
      <email>thomas.martin@klinikum-bremen-mitte.de</email>
    </contact_backup>
    <investigator>
      <last_name>Johann Ockenga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Martin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coburg Klinikum</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Dessau Städtisches Klinikum</name>
      <address>
        <city>Dessau</city>
        <zip>06847</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dresden Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lutz Jacobasch, MD</last_name>
      <email>jacobasch@onkologie-dresden.net</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Wolf, MD</last_name>
      <email>wolf@onkologie-dresden.net</email>
    </contact_backup>
    <investigator>
      <last_name>Lutz Jacobasch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Wolf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erlangen Universitätsklinikum</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Fietkau, MD</last_name>
      <phone>++49(0) 9131 85</phone>
      <phone_ext>33968</phone_ext>
      <email>st-studiensekretariat@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Semrau, MD</last_name>
      <phone>++49(0) 9131 85</phone>
      <phone_ext>33968</phone_ext>
      <email>st-studiensekretariat@uk-erlangen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Rainer Fietkau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabine Semrau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Esslingen Klinikum, Hämatologie/Onkologie</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Geißler, MD</last_name>
      <email>g.kaiser@klinikum-esslingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Sven Weßendorf, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Michael Geißler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carsten Schwänen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frankfurt/Main Universitätsklinikum</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus M Rödel, MD</last_name>
      <email>claus.roedel@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Detlef Imhoff, MD</last_name>
      <email>strahlentherapie@kgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Claus M Rödel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Detlef Imhoff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frechen PIOH</name>
      <address>
        <city>Frechen</city>
        <zip>50226</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Freiburg Universitätsklinikum</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Wittel, MD</last_name>
      <email>uwe.wittel@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Ulrich T Hopt, MD</last_name>
      <email>ulrich.hopt@uniklinik-freiburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Uwe Wittel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrich T Hopt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Friedrichshafen Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Friedrichshafen</city>
        <zip>88045</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmut Oettle, MD</last_name>
      <email>helmut.oettle@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Frank Mayer, MD</last_name>
      <email>frank.mayer@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Helmut Oettle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Mayer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologisches Zentrum Oberland, Klinikum Garmisch-Partenkirchen</name>
      <address>
        <city>Garmisch-Partenkirchen</city>
        <zip>82467</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Göppingen Alb-Fils-Kliniken</name>
      <address>
        <city>Göppingen</city>
        <zip>73035</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Göttingen Universitätsmedizin</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ghadimi, MD</last_name>
      <email>michael.ghadimi@chirurgie-goettingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Hendrik Wolff, MD</last_name>
      <email>hendrik.wolff@med.uni-goettingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Ghadimi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hendrik Wolff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Halle St. Elisabeth und St. Barbara Krankenhaus</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Opitz, MD</last_name>
      <email>b.opitz@krankenhaus-halle-saale.de</email>
    </contact>
    <contact_backup>
      <last_name>Judith Böhme, MD</last_name>
      <email>j.boehme@krankenhaus-halle-saale.de</email>
    </contact_backup>
    <investigator>
      <last_name>Bernhard Opitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith Böhme, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamburg Hämatologisch-Onkologischer Schwerpunkt</name>
      <address>
        <city>Hamburg</city>
        <zip>22457</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Bertram, MD</last_name>
      <email>m.bertram@onkologie-partner.de</email>
    </contact>
    <contact_backup>
      <last_name>Sigrun Müller-Hagen, MD</last_name>
      <email>s.mueller-hagen@onkologie-partner.de</email>
    </contact_backup>
    <investigator>
      <last_name>Mathias Bertram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sigrun Müller-Hagen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heilbronn SLK-Kliniken</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Martens, MD</last_name>
      <email>uwe.martens@slk-kliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Markus Lindauer, MD</last_name>
      <email>markus.lindauer@slk-kliniken.de</email>
    </contact_backup>
    <investigator>
      <last_name>Uwe Martens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus Lindauer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Bernward Krankenhaus GmbH</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrich Kaiser, Prof.</last_name>
      <phone>+49 5121 90</phone>
      <phone_ext>1274</phone_ext>
      <email>prof.dr.u.kaiser@bernward-khs.de</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Heide, M.D.</last_name>
      <phone>+49 512190</phone>
      <phone_ext>1433</phone_ext>
      <email>dr.t.heide@bernward-khs.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Homburg Universitätsklinikum</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Jena Universitätsklinikum</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Udo Lindig, MD</last_name>
      <email>udo.lindig@med.uni-jena.de</email>
    </contact>
    <contact_backup>
      <last_name>Ekkehard Eigendorff, MD</last_name>
      <email>ekkehard.eigendorff@med.uni-jena.de</email>
    </contact_backup>
    <investigator>
      <last_name>Udo Lindig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ekkehard Eigendorff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Köln Studiengesellschaft</name>
      <address>
        <city>Köln</city>
        <zip>50674</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Köln Universitätsklinikum</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Waldschmidt, MD</last_name>
      <email>dirk.waldschmidt@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Arnulf H Hölscher, MD</last_name>
      <email>Arnulf.Hoelscher@uk-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Dirk Waldschmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnulf H Hölscher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Köln Kliniken</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Landshut Klinikum</name>
      <address>
        <city>Landshut</city>
        <zip>84034</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Leer MVM</name>
      <address>
        <city>Leer</city>
        <zip>26789</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lothar Müller, MD</last_name>
      <email>lothar.mueller@onkologie-leer.de</email>
    </contact>
    <contact_backup>
      <last_name>Carsten Janßen, MD</last_name>
      <email>carsten.janssen@onkologie-leer.de</email>
    </contact_backup>
    <investigator>
      <last_name>Lothar Müller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carsten Janßen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leipzig UCCL</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Lordick, MD</last_name>
      <email>florian.lordick@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Gertraud Stocker, MD</last_name>
      <email>gertraud.stocker@medizin.uni-leipzig.de</email>
    </contact_backup>
    <investigator>
      <last_name>Florian Lordick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gertraud Stocker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leverkusen Klinikum</name>
      <address>
        <city>Leverkusen</city>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Charles, MD</last_name>
      <email>astrid.charles@klinikum-lev.de</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Hammans, MD</last_name>
      <email>stephanie.hammans@klinikum-lev.de</email>
    </contact_backup>
    <investigator>
      <last_name>Astrid Charles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Hammans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magdeburg Universitätsklinikum</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Garlipp, MD</last_name>
      <email>benjamin.garlipp@med.ovgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Kerstin Schütte, MD</last_name>
      <email>kerstin.schuette@med.ovgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Benjamin Garlipp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kerstin Schütte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magdeburg Klinikum</name>
      <address>
        <city>Magdeburg</city>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karsten Ridwelski, MD</last_name>
      <email>karsten.ridwelski@klinikum-magdeburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Kahl, MD</last_name>
      <email>christoph.kahl@klinikum-magdeburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Karsten Ridwelski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Kahl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mainz Universitätsmedizin</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Mannheim Universitätsmedizin</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolai Härtel, MD</last_name>
      <email>nicolai.haertel@umm.de</email>
    </contact>
    <contact_backup>
      <last_name>Nadine Schulte, MD</last_name>
      <email>nadine.schulte@umm.de</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolai Härtel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadine Schulte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marburg Universitätsklinikum</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>München Großhadern LMU</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Heinemann, MD</last_name>
      <email>volker.heinemann@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Böck, MD</last_name>
      <email>sekrmed3@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Volker Heinemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Böck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Münster Universitätsklinikum</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Th. Eich, MD</last_name>
      <email>Hans.Eich@ukmuenster.de</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Anthoni, MD</last_name>
      <email>christoph.anthoni@ukmuenster.de</email>
    </contact_backup>
    <investigator>
      <last_name>Hans Th. Eich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Anthoni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oldenburg Pius Hospital</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Griesinger, MD</last_name>
      <email>frank.griesinger@pius-hospital.de</email>
    </contact>
    <contact_backup>
      <last_name>Hagen Flach, MD</last_name>
      <email>hagen.flach@pius-hospital.de</email>
    </contact_backup>
    <investigator>
      <last_name>Frank Griesinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hagen Flach, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ostfildern Paracelsus Krankenhaus Ruit</name>
      <address>
        <city>Ostfildern</city>
        <zip>73760</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Regensburg Krankenhaus Barmherzige Brüder</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Moosmann, MD</last_name>
      <email>nicolas.moosmann@barmherzige-regensburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Anke Schlenska-Lange, MD</last_name>
      <email>anke.schlenska-lange@barmherzige-regensburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolas Moosmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anke Schlenska-Lange, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regensburg Universitätsklinikum</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Hautmann, MD</last_name>
      <email>matthias.hautmann@klinik.uni-regensburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Oliver Koelbl, MD</last_name>
      <email>oliver.koelbl@ukr.de</email>
    </contact_backup>
    <investigator>
      <last_name>Matthias Hautmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oliver Koelbl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stuttgart Klinikum SCC</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Illerhaus, MD</last_name>
      <email>g.illerhaus@klinikum-stuttgart.de</email>
    </contact>
    <contact_backup>
      <last_name>Alberta-May Daraban, MD</last_name>
      <email>a.daraban@klinikum-stuttgart.de</email>
    </contact_backup>
    <investigator>
      <last_name>Gerald Illerhaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alberta-May Daraban, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stuttgart Marienhospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Traunstein Klinikum</name>
      <address>
        <city>Traunstein</city>
        <zip>83278</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas W. Kubin, MD</last_name>
      <email>thomas.kubin@klinikum-traunstein.de</email>
    </contact>
    <contact_backup>
      <last_name>Elke Hagenreiner, MD</last_name>
      <email>elke.hagenreiner@klinikum-traunstein.de</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas W. Kubin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elke Hagenreiner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trier Mutterhaus der Borromäerinnen</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Trier Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Tübingen Universitätsklinikum</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ulm Universitätsklinikum</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Würzburg CCC Mainfranken</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Kunzmann, MD</last_name>
      <email>kunzmann_v@klinik.uni-wuerzburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Michaela Metz, MD</last_name>
      <email>metz_m2@klinik.uni-wuerzburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Volker Kunzmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michaela Metz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 4, 2013</study_first_submitted>
  <study_first_submitted_qc>April 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2013</study_first_posted>
  <last_update_submitted>June 19, 2019</last_update_submitted>
  <last_update_submitted_qc>June 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>chemoradiotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>FOLFIRINOX</keyword>
  <keyword>gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

